NervGen Pharma (NervGen Pharma) Ending Cash Position : $22.39 Mil (As of Mar. 2024)

View and export this data going back to 2019. Start your Free Trial

What is NervGen Pharma Ending Cash Position?

NervGen Pharma's Ending Cash Position for the quarter that ended in Mar. 2024 was $22.39 Mil.

NervGen Pharma's quarterly Ending Cash Position declined from Sep. 2023 ($10.93 Mil) to Dec. 2023 ($8.69 Mil) but then increased from Dec. 2023 ($8.69 Mil) to Mar. 2024 ($22.39 Mil).

NervGen Pharma's annual Ending Cash Position increased from Dec. 2021 ($13.23 Mil) to Dec. 2022 ($16.53 Mil) but then declined from Dec. 2022 ($16.53 Mil) to Dec. 2023 ($8.69 Mil).

NervGen Pharma Ending Cash Position Historical Data

The historical data trend for NervGen Pharma's Ending Cash Position can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

NervGen Pharma Ending Cash Position Chart

NervGen Pharma Annual Data

Trend

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Ending Cash Position

Get a 7-Day Free Trial

3.12

4.38

13.23

16.53

8.69

NervGen Pharma Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Ending Cash Position	Get a 7-Day Free Trial															13.17	12.11	10.93	8.69	22.39

NervGen Pharma Ending Cash Position Calculation

Ending Cash Position is the cash and cash equivalents balance at the end of the accounting period, as indicated on the Cash Flow statement. It is equal to the Beginning Cash Position plus the Net Change in Cash.

NervGen Pharma's Ending Cash Position for the fiscal year that ended in Dec. 2023 is calculated as

Ending Cash Position	=	Beginning Cash Position	+	Net Change in Cash
	=	16.736	+	-8.045
	=	8.69

NervGen Pharma's Ending Cash Position for the quarter that ended in Mar. 2024 is calculated as

Ending Cash Position	=	Beginning Cash Position	+	Net Change in Cash
	=	8.614	+	13.774
	=	22.39

NervGen Pharma Ending Cash Position Related Terms

Thank you for viewing the detailed overview of NervGen Pharma's Ending Cash Position provided by GuruFocus.com. Please click on the following links to see related term pages.

NervGen Pharma (NervGen Pharma) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » NervGen Pharma Corp (OTCPK:NGENF) » Definitions » Ending Cash Position

Comparable Companies

Traded in Other Exchanges

9UA:Germany NGEN:Canada

Address

2955 Virtual Way, Suite 480, Vancouver, BC, CAN, V5M 4X6

Website

https://www.nervgen.com

NervGen Pharma Corp is a biotech company dedicated to creating innovative solutions for the treatment of nerve damage and neurodegenerative diseases. The company is developing drugs for the treatment of spinal cord injury, multiple sclerosis, and Alzheimer's disease. It operates in a single segment, which is the research and development of pharmaceutical drugs.

NervGen Pharma (NervGen Pharma) Headlines

From GuruFocus

NervGen Pharma To Webcast At VirtualInvestorConferences.com July 11th

By PRNewswire PRNewswire • 07-09-2019